Publications by authors named "Giovanni Battista Bonfioli"
Article Synopsis
- Heart Failure with Preserved Ejection Fraction (HFpEF) is a complex condition often linked with diastolic dysfunction and chronic systemic inflammation, heavily influenced by comorbidities like diabetes, obesity, and aging.
- Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs), particularly semaglutide, show promise in improving the health of obese patients with HFpEF by reducing inflammation and oxidative stress while enhancing blood vessel function.
- Recent clinical trials have highlighted the potential of GLP-1 RAs to significantly improve the quality of life and lower inflammatory markers, suggesting their importance in managing HFpEF and promoting cardiovascular health in affected individuals.
Article Synopsis
- - The study aimed to compare the new Mayo transthyretin amyloidosis cardiomyopathy (ATTR-CM) score with older diagnostic tools for cardiac amyloidosis (CA) in patients suspected of having the condition.
- - Analyzing 362 patients, it was found that the ATTR-CM score effectively distinguished between transthyretin CA (ATTR-CA), immunoglobulin light chain CA (AL-CA), and no CA, showing strong diagnostic performance with area under the curve (AUC) values above 0.795.
- - The results indicated that the ATTR-CM score outperformed previous scoring systems like the increased wall thickness (IWT) and AMYLoidosis Index (AMYLI
Endocarditis, a serious infectious disease, remains a diagnostic challenge in contemporary clinical practice. The advent of advanced imaging modalities has contributed significantly to the improved understanding and management of this complex disease. 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) imaging has shown remarkable potential in improving the diagnostic accuracy of endocarditis.
View Article and Find Full Text PDFArticle Synopsis
- The study focused on the prevalence and impact of mitral regurgitation (MR) and tricuspid regurgitation (TR) in patients with cardiac amyloidosis (CA), highlighting a lack of existing research on this topic.
- Among 538 patients analyzed, 44.6% had no significant MR/TR, while a significant portion experienced varying degrees of MR or TR, with common causes being atrial functional issues and right ventricular overload.
- Results indicated that patients with MR/TR had worse health outcomes, including higher hospitalization rates for heart failure, more symptoms, and increased risk of death or worsening heart failure, with TR presenting the most severe risks.
Sodium glucose co-transporter 2 inhibitors and quality of life in patients with heart failure: a comprehensive systematic review and meta-analysis of randomized controlled trials.
Eur Heart J Cardiovasc Pharmacother
February 2024
Article Synopsis
- Sodium glucose co-transporter 2 inhibitors (SGLT2i) are key treatments for heart failure (HF), but their effects on patients' quality of life (QoL) haven't been extensively studied.
- This systematic review analyzed data from 23 randomized clinical trials focusing on the impact of SGLT2i on QoL using the Kansas City Cardiomyopathy Questionnaire (KCCQ-OSS).
- The results indicated a significant improvement in QoL for patients taking SGLT2i, with notable benefits observed at both 3 and 6 months, especially in those with recent worsening heart failure episodes.
Right ventricular to pulmonary artery coupling and outcome in patients with cardiac amyloidosis.
Eur Heart J Cardiovasc Imaging
September 2023
Article Synopsis
- The study aimed to determine how the coupling between the right ventricle and pulmonary artery (RV-PA) can predict outcomes in patients with cardiac amyloidosis caused by transthyretin (ATTR) or immunoglobulin light-chain (AL).
- It included 283 patients and found that a TAPSE/PASP ratio of less than 0.45 indicated older age, more severe symptoms, and a higher risk of death or hospitalization due to heart failure.
- The TAPSE/PASP ratio was shown to be a better prognostic indicator than either measurement alone, being significantly linked to mortality and heart failure risks in both ATTR and AL types of cardiac amyloidosis.
The aorta and aortic wall have a complex biological system of structural, biochemical, biomolecular, and hemodynamic elements. Arterial stiffness could be considered a manifestation of wall structural and functional variations, and it has been revealed to have a strong connection with aortopathies and be a predictor of cardiovascular risk, especially in patients affected by hypertension, diabetes mellitus, and nephropathy. Stiffness affects the function of different organs, especially the brain, kidneys, and heart, promoting remodeling of small arteries and endothelial dysfunction.
View Article and Find Full Text PDFArticle Synopsis
- Growing awareness and advancements in diagnostic tools have significantly improved the management of amyloid transthyretin cardiomyopathy (ATTR-CM) in recent years.
- While traditional supportive therapies offer limited relief for heart failure symptoms, new disease-modifying treatments have emerged, targeting the amyloid proteins involved in the condition.
- Tafamidis is the only approved drug for ATTR-CM, with additional treatments like patisiran and inotersen showing promise for hereditary ATTR polyneuropathy, and ongoing trials exploring innovative therapies like vutrisiran and eplontersen.